
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Because type 2 diabetes is associated with substantial burdens on health care resources in the United States, treatment approaches that minimize complications and reduce health care costs are needed.
Click PLAY to watch the video abstract.
Click
Click






